Answers from WP - a good read, page-190

Its the point I have made recently. 3D is a Premium product which Eire tells us commands a healthy price. The action is in the USA and in the paediatric/neonatal area. 3D and Neo products. The company should pursue this market and expand the number of hospitals using the product. Every quality neonatal hospital is worth $1m to us annually. Lets target 100 hospitals world wide and announce every time a new hospital comes on board. Like when Great Ormond Street joins up etc. France will have 5 or 6 , the same for Germany, 5 for Spain. Honkers, Canada, Japan. etc. As soon as it becomes the best in class the best centres will be clambering to come on board. That is when the premium increases. We seem to have a unique product so concentrate on it and the Neo product. Spending money in Europe doing repair work on aortic valves seems dubious presently unless the company is aware of significant future trends which they should communicate to us and to the business community.Other wise go neonatal where we have traction and a unique product.